The development of new drugs reportedly takes a minimum of 10 years and costs at least $720 million.(1 trillion won) Nevertheless, the success rate remains around 10%.

Here in this forum, we will explore the limitations of the Korean biohealth industry, which strives to survive amidst the stringent regulatory environment established by the US Food and Drug Administration (FDA) and the influence of large global pharmaceutical companies, despite its advanced technological capabilities.

Ultimately, we aim to explore potential alternative measures to overcome these limitations.